Calling both treatments "anti-aging" causes trouble. Menopause symptoms and clinically low testosterone are different problems. The patients, benefits, and risks do not merge just because both treatments involve hormones.
I will not pretend this article can make the decision for you. A qualified doctor needs your symptoms, history, risks, and the tests that fit the diagnosis. What I can do is keep each result tied to the people who were studied. Sales copy tends to drop that part first.
What do HRT and TRT mean?
On this page, HRT means menopausal hormone therapy. Doctors use it for menopause symptoms and to protect bone in some women.
TRT means testosterone replacement therapy. The medical name for the condition it treats is male hypogonadism, which means the body is not making enough testosterone. The Endocrine Society says the diagnosis needs symptoms or signs plus blood levels that are clearly and repeatedly low. It recommends against screening every man and treating a number by itself (Endocrine Society clinical practice guideline).
So these are not two versions of the same youth treatment. They answer different medical problems.
What can menopausal hormone therapy help?
Menopausal hormone therapy is the most effective treatment for hot flashes and night sweats. It can also help genital and urinary symptoms of menopause, and it prevents bone loss and fractures. Those findings come from the 2022 North American Menopause Society position statement.
The same statement says age and time since menopause change the average balance of benefit and risk. For women who start treatment before age 60 or within 10 years of menopause, the balance is generally more favorable, as long as no health condition rules treatment out. For women who start after age 60 or more than 10 years after menopause, the balance is less favorable. Their absolute risks of coronary heart disease, stroke, blood clots in veins, and dementia are higher.
Those are group findings, not a green light based on a birthday. A guideline cannot see the medical history sitting in front of a doctor.
What are the main HRT tradeoffs?
HRT can relieve hard symptoms and protect bone. Some forms also raise the chance of serious harm.
A 2025 Cochrane review pooled 24 studies with about 45,660 women. Combined estrogen and progestogen therapy may raise stroke and vein-clot risks. It probably raises breast cancer risk while lowering fracture risk. Estrogen-only therapy probably raises stroke risk, but showed little effect on breast cancer or vein clots (Cochrane review of long-term hormone therapy).
The review came with a big catch. Only about 30 percent of the women were ages 50 to 59, the main group seeking treatment for symptoms. The trials also used oral treatment, so their results may not map cleanly to all care today. That does not erase the risks. It tells us not to force one risk number onto every woman.
I do not think the evidence needs help from either extreme. "Always safe" and "always dangerous" both say more than these studies can support.
What can testosterone therapy help?
The Testosterone Trials enrolled 788 men age 65 and older. All had symptoms and confirmed low testosterone. Treatment improved sexual activity and desire. It also improved erectile function, bone density, estimated bone strength, and mild anemia (Snyder and colleagues, Lessons From the Testosterone Trials).
The marketing version is much bigger than that result. Physical function and vitality changed little. Mood improved by a small amount, and memory did not improve.
The trials lasted one year. Researchers saw a greater rise in noncalcified coronary artery plaque volume. That is a measure of plaque buildup in the heart's arteries. They also saw raised hemoglobin, a blood-count problem that needs medical monitoring. One year was not enough to settle long-term heart or prostate safety.
What did the largest heart-safety trial find about TRT?
The largest modern heart trial did not show a higher rate of its main combined outcome during the study period.
TRAVERSE studied more than 5,200 men ages 45 to 80. They had symptoms, low testosterone, and preexisting cardiovascular disease or high cardiovascular risk. The trial tested whether TRT kept its main event rate within a preset margin of the placebo rate, and it passed. The outcome covered cardiovascular death, heart attack, or stroke. About 7 percent of each group had one of those events over roughly 22 months (American College of Cardiology summary of TRAVERSE).
That is good news, with a fence around it. It applies to the men and the main outcome the trial studied.
Other safety signals went the wrong way. Atrial fibrillation, an irregular heart rhythm, happened more often in the TRT group. So did blood clots in the lungs and sudden kidney injury. These were not the main outcome, so the trial was not built to give a firm answer on each one. They still belong in the decision.
The study also leaves a long view open. It did not test younger, healthy men with low heart risk, and two years cannot answer what happens over decades.
Do HRT or TRT help people live longer?
Not proven. The evidence here does not show that HRT or TRT extends life. Both are treatments for defined medical problems, not proven longevity tools.
The long-term HRT review found little or no difference in heart attacks overall. It also found some higher risks and a lower fracture risk, depending on the treatment. That is a tradeoff, not proof of a longer life.
The TRT trials give us an even shorter view. They measured specific benefits and near-term safety outcomes. They do not tell us whether TRT changes lifespan over many years.
Anyone promising certainty beyond that is selling more than the trials found.
What questions belong in the doctor conversation?
Ask what exact problem the treatment is meant to solve and what shows that the diagnosis fits.
For TRT, symptoms and repeatedly low blood levels both matter. For menopausal hormone therapy, the balance can change with the symptom and the woman's age. Time since menopause and health history matter too. So do any conditions that rule treatment out.
These are the questions I would bring:
- What exact symptom or diagnosed problem is this meant to treat?
- What evidence shows that the diagnosis fits me?
- Which part of my history changes the likely benefit or risk?
- What is still unknown for someone like me?
- How will my doctor watch for benefit or harm?
That is a doctor conversation, not a checklist for treating yourself. If a sales pitch comes before the diagnosis, slow the conversation down.
If this page raised more questions than it answered, good. The next stop is the Longevity research library, and after that my guide to VO2 max and mortality risk, which holds fitness claims to the same rules I used here. All of it rolls up into the rest of my guides, one sourced page at a time.
What are readers asking?
Can symptoms alone prove that a man has low testosterone?
No. The Endocrine Society says the diagnosis needs symptoms or signs plus testosterone levels that are clearly and repeatedly low on proper testing. It recommends against routine screening of all men.
Did the big trials prove that HRT and TRT are safe?
No. The trials answered narrow questions in defined groups. HRT had real symptom and bone benefits with risks that changed by treatment and patient. TRT was reassuring on one main heart outcome, but other safety signals and long-term questions remain.
Want this research standard applied to your business?
This page is how I work when the stakes are health: real sources first, and the limit printed next to the claim. I do not sell hormone products or health advice. If you want your own business's pages held to the same standard, book a call.